AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06010602 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: İlioinguinal-İliohipogastric nerve block
Description: For all patients, postoperative analgesia was planned as paracetamol 1g four times a day for the first 24 hours after surgery. Patients with Numeric Rating Scale (NRS) scores greater than 3 at 2, 4, 8, 12, and 24 hours postoperatively were administered rescue analgesia with tramadol hydrochloride at a dose of 1mg/kg.
Study NCT06694675 — intervention group
Intervention type: DRUG
Intervention: propofol
Description: Propofol 9\~15mg/kg/h
Study NCT06630260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Supplied as 0.8mg capsules.
Study NCT06630260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Supplied as 200mg tablets.
Study NCT06630260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be supplied as 5, 20, 100, 140, 180 or 250 mg hard capsules.
Study NCT06688227 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Isolated Core Stability Program
Description: The control group consists of basic core exercises which include the activation of transversusabdominins and multifidus muscles and progressive strengethening of these muscles in all positions using swiss balls and floor mats. All exercises were done for at least 3 sets of 15 repetitions to build proper core stability.
Study NCT06688227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Core Stability Program
Description: An individualized protocol was designed for these cricketers targeting static and dynamic core stability, with integration of balance, endurance and power component.~Tranversusabdominis and multifidus strengthening is combined with upper extremity motions to work on the fast bowling action i.e throwing of the players.~At the same time lower extremity balance and strengthening is also included to ensure the high speed of sprint.
Study NCT06687564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: A skin biopsy and a blood sample will be taken to culture the iPS cells and intestinal organoids.
Study NCT06687564 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: A skin biopsy and a blood sample will be taken to culture the iPS cells and intestinal organoids.
Study NCT06688266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve Gliding Exercises
Description: This group will receive 25-minute session of nerve gliding exercises per session five days a week for six weeks. It will include: Warm-Up (5 minutes)~Neural Gliding of the upper quadrant:~Median nerve glide (5 minutes) Ulnar nerve glide (5 minutes) Radial nerve glide (5 minutes) Cool Down (5 minutes)
Study NCT06688266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand Grip Strength Exercises
Description: This group's participants will also receive a 25 -minute session five days per week (for six weeks). Warm-Up (5 minutes) Conventional Grip Strength Exercises (15 Minutes)~* Tendon gliding sequence of exercises for hand~* Squeezing a rubber ball or stress ball~* Dead Hang Cool Down (5 Minutes)
Study NCT04862650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04862650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given IV
Study NCT04862650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT06696443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suzetrigine
Description: Tablets for oral administration.
Study NCT06702124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine 4Mg/24Hrs Patch
Description: Rotigotine 4 mg/24Hrs administration for 24 weeks
Study NCT06702124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration for 24 weeks
Study NCT06698536 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aktiia G2C
Description: Study subjects are asked to stay seated while 3 successive measurements are taken with the Aktiia G2C device under investigation (BP and PR) and two references (Aktiia Bracelet G2 and Aktiia Init I1 oscillometric cuff).
Study NCT06626503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone based ERAS
Description: Children randomized to the methadone arm will receive standardized perioperative care and analgesia, including intraoperative intravenous methadone (0.1 mg/kg up to a maximum of 5 mg before incision and 0.05 mg at the end of surgery) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
Study NCT06626503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC non-methadone based group
Description: Children randomized to the standard-of-care arm will receive standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards.
Study NCT06706817 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: IMP. Subcutaneous injection. Unit dose strengths 210 mg.
Study NCT06714552 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galacto-Oligosaccharide
Description: 24.0 g Oligomate® in 100 mL water
Study NCT06714552 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose
Description: 17.8 g glucose in 100 mL water
Study NCT06713239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleerly Labs and Cleerly ISCHEMIA
Description: Participants in the coronary plaque-based care arm will have CCTA at baseline. CCTA images will be redacted and uploaded to Cleerly, interpreted using Cleerly Labs and Cleerly ISCHEMIA, and archived.
Study NCT06687967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
Study NCT06687967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
Study NCT06718348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of the Exoskeleton JAPET.W
Description: Phsysiotherapy sessions with the support of the Exoskeleton JAPET.W
Study NCT06717750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSCJC3456 tablet
Description: * Phase Ia: Single and Multiple Dose Escalation.~  1. Dosage form: tablet.~ 2. Dosage: 7 dose groups, 5 mg, 15 mg, 30 mg, 45 mg, 60 mg, 80 mg, 100 mg.~ 3. Frequency: once daily (tentative), or twice daily and other options (adjusted based on the results of the preliminary trials).~ 4. Duration: 5 mg(days 1-28; 28 days per cycle), other groups (days 1-21; 28 days per cycle) .~* Phase Ib: Cohort Expansion. Dosage and dosing regimen: according to the recommended dosage and dosing cycle from the Phase Ia study.
Study NCT06718634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M08D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT06724523 — intervention group
Intervention type: BEHAVIORAL
Intervention: Business-as-usual instruction
Description: Deaf children are receiving business-as-usual instruction in sign language in deaf education programs.
Study NCT06722326 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Hydrogen-rich water
Description: Hydrogen-rich water with 12 mg of hydrogen per serving
Study NCT06722326 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Supplement: Control water
Description: Control water with 0 mg of hydrogen per serving
Study NCT06731166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-care
Description: Videomonitoring provide by cardiovascular nurses
Study NCT06722560 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1 hormone
Description: s.c. continuous infusion for 72 hours using an insulin pump
Study NCT06722560 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: s.c. continuous infusion for 72 hours using an insulin pump
Study NCT06743516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticojejunostomy with external stent
Description: Inserting ureteric stent at the pancreaticojejunostomy site
Study NCT06743516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticojejunostomy without external stent
Description: Only Pancreaticojejunostomy without inserting external stent
Study NCT06744231 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Prior to implementation of the Thriving Hearts package of services, people living in participating counties will receive usual care for pregnancy, birth, and postpartum services. The study team will quantify existing services using a study-developed usual care assessment instrument.
Study NCT06744231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thriving Hearts
Description: Thriving Hearts is a collaboration among LHDs in ten North Carolina counties. At the individual level, pregnant individuals will self-screen for HDP risk during prenatal visits, and those at risk will be provided a Mama Hearts Care Kit, including a home blood pressure monitor, low dose aspirin, and culturally tailored educational materials.~At the healthcare provider level, burnout and compassion fatigue will be addressed through skill-building activities, including training in the Community Resilience and Mindfulness-Based Stress Reduction.~At the community level, Loving Connection will provide proactive material and social support through Community Health Workers, text messaging-based communication, a medical legal partnership, and capacity-building support for community-based organizations.
Study NCT06720727 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: craniospinal irradiation
Description: Delivering radiotherapy to brain, spinal cord and its covering membrane.
Study NCT06747390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Injectable Solution
Description: 1% lidocaine will be injected under direct visualization (not exceeding the maximum tolerated dose of 4.5 mg/kg body weight) into the primary tumor with the aim to distribute the lidocaine evenly into the tumor.
Study NCT06756295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: individualized tumor FAST vaccine combination (including adjuvant)
Description: Using the patient's individual tumor tissue, an autologous FAST (Fragmented Autoantigen Stimulated T-cell Immunotherapy) vaccine is prepared.
Study NCT06756074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reinforced pancreaticojejunostomy with tissue adhesive glue modified cyanoacrylate (glubran 2)
Description: pancreaticojejunostomy was done with application of glubran 2: The blister pack was opened, and the sterile single-dose vial was released directly onto the operating table in a sterile environment, Draw the Glubran 2 out of the single-dose vial using a sterile syringe then put the syringe into applicator Glubran 2 was applied into anastomosis by applicator in spraying manner . Whenever possible, the area to be treated should be cleaned before application. When applied in such a minimal amount, once it had polymerized, Glubran 2 formed a thin adhesive layer. It was therefore essential not to apply more than one drop in the same point. A second layer of Glubran 2 may not be applied until the first had polymerized. Any excess product was removed using a dry swab within 5-6 seconds after application. Glubran 2 was not touched after application until the polymerization reaction is complete, as it may detach or not produce the desired effect.
Study NCT06756074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2)
Description: Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2)
Study NCT06132256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Administered as intravenous (IV) infusion
Study NCT06132256 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match axatilimab administered as IV infusion. Placebo will not contain active ingredient.
Study NCT06747858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-032
Description: CFTR mRNA formulated in lipid nanoparticles
Study NCT06759935 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser therapy
Description: sham laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week.
Study NCT06759935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser therapy
Description: laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week.
Study NCT06759935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy/exercise protocol
Description: physiotherapy/exercise protocol represents the standard of care (SOC) and the program includes Codman's pendulum exercise, range of motion (ROM) exercises, stretching and isometric strengthening exercises, for 4 consecutive weeks with a minimum of 3 sessions per week.
Study NCT06759935 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: physiotherapy/exercise protocol
Description: physiotherapy/exercise protocol represents the standard of care (SOC) and the program includes Codman's pendulum exercise, range of motion (ROM) exercises, stretching and isometric strengthening exercises, for 4 consecutive weeks with a minimum of 3 sessions per week.
Study NCT06761092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Dexmedetomidine for Post-Anesthesia Delirium in Preschool Children
Description: Nebulization with the anesthetic drug dexmedetomidine at a dose of 2 mcg/kg body weight, diluted to 3 ml with 0.9% normal saline, administered before the induction of anesthesia in the reception area.~After the anesthesia, primary data collection is conducted by recovery room staff who are blinded to the treatment and control groups. Data includes scores or levels of post-anesthesia delirium or agitation assessed using the PAED score at 15, 30, 60, and 120 minutes post-surgery in the recovery room
Study NCT06761092 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized 0.9% Normal Saline
Description: Nebulization with normal saline 0.9% 3 ml, administered before the induction of anesthesia in the reception area. After the anesthesia, primary data collection is conducted by recovery room staff who are blinded to the treatment and control groups. Data includes scores or levels of post-anesthesia delirium or agitation assessed using the PAED score at 15, 30, 60, and 120 minutes post-surgery in the recovery room
Study NCT05837286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oval-8 ® Orthosis
Description: The experimental group will consist of receiving a PIP joint on the day they receive their cortisone injection. The Oval-8 ® will be issued to the subject by an Occupational Therapist to ensure correct fit and comfort as well as given written instructions for night use. The orthosis will be worn at night for 6-week duration. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.
Study NCT05837286 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone injection only
Description: The control group will receive a cortisone injection and be instructed to move their fingers normally
Study NCT06754540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Description: Azacitidine 32mg/m2
Study NCT06767007 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Patients will begin SBRT treatment within 2 weeks after the first round of chemotherapy. Intensity-modulated radiation therapy (IMRT) technology will be used, with a target gross tumor volume (GTV) of 5-8Gy/5 sessions, a total dose of 25-40Gy equivalent to a biological effective dose (BED) of 37.5-72Gy, administered from Monday to Friday. For patients who have previously received pelvic radiotherapy, the re-irradiation dose will be 3-5Gy/5 sessions, a total dose of 15-25Gy equivalent to a BED of 19.5-37.5Gy, administered from Monday to Friday.
Study NCT06767007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1
Description: The PD-1 monoclonal antibody used is Sintilimab 200mg every 3 weeks
Study NCT06767007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: First-line chemotherapy regimen of rectal cancer, using a second-line regimen primarily based on fluorouracil, such as a tri-weekly CAPOX or a bi-weekly mFOLFOX6/FOLFIRI/FOLFOXIRI + targeted therapy
Study NCT06763263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Children and their parents in this group will be informed about the research and their verbal and written consent will be obtained. A questionnaire will be filled out before the application. Then, the child will be allowed to choose one of the superhero clothes he/she wants in his/her room and will be allowed to wear the clothes. The superhero figure will be shown to him/her and he/she will be allowed to play with the clothes and the figure for 2 hours.
Study NCT06763263 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The children in this group and their parents will be informed about the research and their verbal and written consent will be obtained. A questionnaire will be filled out before the application. The children will be evaluated in terms of their reactions after their hospitalization, they will not be dressed in any clothing and no superhero figures will be used. Then the questionnaire will be filled out again and scoring will be done. In order to prevent ethical bias before discharge, the child will be dressed in a superhero costume and will be allowed to spend time with the clothing and figure.
Study NCT06767059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Group
Description: Patients will be asked to walk for 30 minutes at least 3 times for 8 weeks. In order to ensure regular follow-up, patients will be asked to write on the walking tracking form when they walk and the number of steps before they start walking and the number of steps after walking using the application.
Study NCT06767059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grounding Group
Description: Patients will be asked to walk with a grounding stick for 30 minutes at least 3 times for 8 weeks. Patients will be asked to fill in the walking follow-up form and grounding follow-up form for regular follow-up.
Study NCT06767839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: The current parameters for the TENS to be applied in the study were determined as 100 Hz, 100 microsecond pulse duration, and asymmetric biphasic waveform. The current intensity will be increased until the person feels a tingling sensation and will be applied for a total of 20 minutes. Two superficial electrodes will be placed to cover the application area to create an effect in deep tissue.
Study NCT06767839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Voltage Pulsed Galvanic Stimulation
Description: YVKGS is a monophasic waveform current with double peaks, short pulse duration and a voltage higher than 100 Volts, the frequency of which can be adjusted optionally. In the study, the current parameters of YVKGS were determined as a frequency of 100 Hz, continuous pulse, double peak monophasic waveform. The current intensity will be applied for 20 minutes at the voltage at which the person feels a tingling sensation. Two superficial electrodes will be placed to cover the application area to create an effect in deep tissue.
Study NCT06767839 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham TENS
Description: The current will be applied to the sham TENS group with the same parameters as the TENS group, and will be reduced and turned off after a while. In TENS application, people normally report that they no longer feel tingling after a few minutes of starting the application. Therefore, it will be explained to the sham TENS group that this situation is normal, and that they no longer feel tingling because they have become accustomed to the applied current.
Study NCT06769828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-FAPI-46
Description: Ga-68-FAPI-46 PET scan in colorectal cancer
Study NCT06759558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuranolone
Description: Zuranolone is a neuroactive steroid that works by modulating the activity of the gamma-aminobutyric acid (GABA) receptor in the brain.
Study NCT06760299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: %25 tension Kinesio tape
Description: I shaped Kinesio tape application with 25% tension
Study NCT06760299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 75% tension Kinesio tape
Description: I shaped Kinesio tape application with 75% tension